Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

One of the largest benefit managers, CVS Health’s Caremark, made the decision to exclude Zepbound in spite of research that found that it resulted in more weight loss than Wegovy, which will ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Despite lower-than-expected first-quarter revenues and a guidance cut for 2025, NVO stock price rose post its earnings release. This is because Novo Nordisk said on the first-quarter call that it ...

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, and sent shares of Septerna into the stratosphere.